Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CPB1 | P15086 | 2/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TLR4 | O00206 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886271 | 1.00 | CCR2 (0.49) | CCR2ALDH1A1GAACPB1CCR3 | |
| SCHEMBL3309443 | 0.82 | KMT2A (0.50) | CCR2ALDH1A1GAACPB1CCR3 | |
| SCHEMBL12101196 | 0.82 | KMT2A (0.50) | CCR2ALDH1A1GAACPB1CCR3 | |
| SCHEMBL3309452 | 0.82 | KMT2A (0.50) | CCR2ALDH1A1GAACPB1CCR3 | |
| SCHEMBL3886268 | 0.81 | CCR2 (0.69) | CCR2ALDH1A1GAACPB1CCR3 | |
| SCHEMBL4929457 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GAACPB1KMT2AL3MBTL1 | |
| SCHEMBL14010470 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GAACPB1KMT2AL3MBTL1 | |
| SCHEMBL2291956 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GAACPB1KMT2AL3MBTL1 | |
| SCHEMBL4929443 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GAACPB1KMT2AL3MBTL1 | |
| SCHEMBL12466098 | 0.81 | CPB1 (0.53) | CCR2ALDH1A1GAACPB1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572813-B2 | Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents; N-[2-[[(cis) -2-[[1- (4-Chlorophenyl)ethyl]amino]cyclohexyl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20060135502-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT | 2006-06-22 | — | — | US | disclosed |
| US-7045521-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040110736-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT (US) | 2004-06-10 | — | — | US | disclosed |
| US-6706712-B2 | RHEUMATIC DISEASES, MULTIPLE SCLEROSIS, ASTHMA, ANTICHOLESTEROL AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-16 | — | — | US | disclosed |
| EP-1343751-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030004151-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-02 | — | — | US | disclosed |
| WO-2002060859-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110736-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | CCR2 5/4885ALDH1A1 1095/4885GAA 4566/4885 |
| US-20030004151-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | CCR2 5/4885ALDH1A1 1095/4885GAA 4566/4885 |
| US-20060135502-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | CCR2 5/4885ALDH1A1 1345/4885GAA 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.